In re application of	:	Confirmation No. 6011
Edwin Southern	:	Attorney Docket No. 99_1175
Serial No. 09/422,803	:	Group Art Unit 1631
Filed October 22, 1999	:	Examiner A. Marschel
ANALYSING POLYNUCLEOTIDE SEQUEN		THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ANSMIT (AGOURD ROM2)3-0975.
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:		
	ınt of \$ <u>18</u>	20.00 to cover Patent Office fees relating to filing
Information Disclosure Statement	• • • • • • •	\$ <u>180.00</u>
A duplicate copy of this paper is being Finance.	g submitte	ed for use in the Accounting Division, Office of
The Commissioner is authorized to classociated with this communication to Depos deficiencies in fees for multiple dependent class	it Accour	
	Respec	tfully submitted,
	Edwin	Southern
WMC/dll.	Ву	Warren M. Cheek, Jr. Registration No. 33,367 Attorney for Applicant
WMC/dlk WENDEROTH, LIND & PONACK, L.L.P. 2033 K St., N.W., Suite 800 Washington, D.C. 20006-1021 Telephone (202) 721-8200 December 20, 2005		[Check No

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Edwin Southern

Serial No. 09/422,803

Filed October 22, 1999



Confirmation No. 6011

Attorney Docket No. 99 1175

Group Art Unit 1631

Examiner A. Marschel

ANALYZING POLYNUCLEOTIDE SEQUENCES

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT

#### SUPPLEMENTAL INFORMATION DISCLOSURE ISTATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

	[]	each U.S. Patent and U.S. Patent application publication;
	[]	each reference previously cited in the international application PCT/; and/or
	[]	each reference previously cited in prior parent application Serial No.
la.	[] T	his Information Disclosure Statement is submitted:
		in three months of the filing date (or of entry into the National Stage) of the e-entitled application, <b>or</b>
	befor	re the mailing of a first Office Action on the merits or the mailing of a first

and thus no certification and/or fee is required.

Office Action after the filing of an RCE,

1b. [X] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [X] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 2. It is hereby certified
  - a. [] that each item of information contained in this Information Disclosure
    Statement was first cited in any communication from a foreign patent
    office in a counterpart foreign application not more than three months
    prior to the filing of the Statement, or
  - b. [] that no item of information contained in the Information Disclosure
    Statement was cited in a communication from a foreign patent office in a
    counterpart foreign application and, to the knowledge of the person
    signing the certification after making reasonable inquiry, was known to
    any individual designated in §1.56(c) more than three months prior to
    the filing of the Statement.
- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
- 4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
  - a. [] a full or partial English language translation submitted herewith,

- b. [] a foreign patent office search report (in the English language) submitted herewith,
- c. [] the concise explanation contained in the specification of the present application at page,
- d. [] the concise explanation set forth in the attached English language abstract,
- e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
- 5. [] A foreign patent office search report citing one or more of the references is enclosed.
- 6. [] Statement Under 37 CFR 1.704(d)

Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart application, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

7. [X] The cited references relate to prior OGT litigations and are explained in the following memorandum.

This memorandum sets out the documents from the various pieces of litigation in which the Applicant, Oxford Gene Technology (OGT), has been involved in the US and in the UK that could bear on claim construction or validity issues and that could bear on whether or not there is an interference in fact. These documents are listed on the seventeen (17) attached PTO-1449 forms as Documents 1, 3-41 and 43-132 (Documents 2 and 42 have been deleted prior to filing as lacking relevance). The cited documents are also identified sequentially hereinbelow by the same Document No. for the Examiner's convenient reference. There are further documents from the US proceedings which are set out in the court dockets, but the Applicant does not believe that these contain argument or evidence that could be relevant. For completeness, copies of the dockets are attached as Document Nos. 133-137. There are additional expert reports not listed in the dockets, but sealed under the various protective orders in the US which the Applicant does not believe relate to these issues.

The Applicant is unable to disclose a number of pleadings and reports from these litigations. In the US a number of documents are subject to protective orders and so cannot be disclosed. Witness statements and experts reports served by a party in UK proceedings are subject to the implied undertaking that they can "only be used for the

purpose of the proceedings in which they are served" (Part 32.12 Civil Procedure Rules). Such evidence will only enter the public domain if there is a trial and the evidence contained in a particular witness statement or report is given in evidence. The Affymetrix litigation in the UK settled before the trial began and, as a result, none of the evidence was ever given. Any disclosure of evidence served by Affymetrix to the Applicant would constitute a breach of the implied undertaking and a contempt of court by the Applicant.

Documents that cannot be disclosed are shown in the list hereinbelow and lack a Document No. While the Applicant is prohibited from disclosing these documents, the Applicant believes that the documents which are disclosed in this IDS provide the same evidence and arguments relevant to the above issues. Thus the Applicant believes that confidential documents merely restate or reargue the same points or evidence raised in the documents which are disclosed.

## Documents in OGT v Affymetrix UK action for infringement and revocation

There is no restriction on OGT in what it does with the evidence it served in the proceedings (other than one confidential witness statement and evidence served in reply that makes reference to Affymetrix evidence). The following documents are potentially relevant to validity of OGT's patents and arguments/evidence on questions of density in relation to Affymetrix's patent that could be relevant to whether there is an interference in fact.

Document No. and Document Description	Date
1. Affymetrix Opening Submission	22.03.01
UK Pleadings on Affymetrix Patent	
2. Deleted	
3. Notice to Admit Facts	28.01.00
4. Second Defendant's Response to the Claimant's Notice to	22.06.00
Admit Facts dated 28.01.00.	
5. Particulars of Independently Valid Claims	22.06.00
6. Statement of Reasons	30.06.00
7. Statement of Opposition	30.06.00
8. Re-Re-Re Amended Particulars of Objections	13.03.01
UK Pleadings on OGT Patent	
9. OGT Amended Particulars of Claim	26.11.99
10. OGT Amended Particulars of Infringement	01.09.00
11. Defence and Counterclaim	06.08.99
12. Amended Particulars of Objections	15.01.01

13. Re-re-Amended Reply and Defence to Counterclaim	02.03.00
OGT Expert Reports from UK Infringement Action	
14. Summary of Expert Report of Dr D Bentley	30.01.01
15-34. Expert Report of Dr D Bentley and Annex 1-19	
35. Expert Report of Prof. W Pfleiderer and Annex 1	19.01.01
36-38. Expert Report of Dr D Wallace Annex 1-2	18.01.01
Supplemental Expert Report of Dr D Bentley	16.03.01
Supplemental Expert Report of Prof. W Pfleiderer	09.03.01
Supplemental Expert Report of Dr D Wallace	06.03.01
Affymetrix Expert Reports from UK Infringement Action	20 01 01
Expert Report of Dr J Wetmur	22.01.01
Expert Report of Dr A Cass	22.01.01
Expert Report of Dr R Gamble	21.01.01
Supplemental Expert Report of Dr J Wetmur	08.03.01
Supplemental Expert Report of Dr A Cass	15.03.01
Supplemental Expert Report of Dr R Gamble	08.03.01
OGT Witness Statements from UK Infringement Action	
39. Witness Statement of Dr Paul Hyman Silverman and	22.11.00
Exhibit PS-1	22.11.00
40-41, 43-44. First Witness Statement of Prof E Southern and Exhibits EMS-1 to EMS-3	01.05.00
45-46. Fifth Witness Statement of Prof E Southern and Annex 4	22.01.01
47. Witness Statement of Peter Jay Coassin	22.01.01
First Confidential Witness Statement of Alan-Philippe Blanchard	19.01.01
48-54. Witness Statement of Dr Timothy Stephen Fell and Exhibits TSF-1 to TSF6	18.01.01
55. Witness Statement of Stewert Leonard Huxley	08.01.01
56. Witness Statement of Martin George Johnson	19.01.01
Sixth Witness Statement of Prof E Southern	09.03.01
Second Witness Statement of Peter Jay Coassin	09.03.01
Witness statement of Dr Uwe Maskos	13.03.01
Affymetrix Witness Statements from UK Infringement Action	
Witness Statement of Dr S Fodor	21.01.01
Witness Statement of V Norviel	10.07.00
Cited References In UK infringement/Revocation Action not cited on PTO File for '637 or '270 Patents	
57. Multi-analyte immunoassay (Elkins)	04.04.89

58. An Immobilised Enzyme Membrane Fabrication Method	22.03.88
using an ink jet nozzle (Kimura et al.)	
59. Strategies for epitope analysis using peptide synthesis	00.05.87
(Geysen et al.)	
60. Human Genome Linking with Cosmids and Yeast Artificial	29.04.89
Chromosomes (Monaco)	
61. GB 1,526,708 (Alfa-Laval)	27.09.78
62. US 4,689,405 (Frank)	25.08.87
63. Statutory Declaration on Presentation entitled "Synthesis of	28.04.89
Oligonucleotides Tethered to a glass surface: Applications in	
the Analysis of Nucleic Acid Sequences" (Southern)	
64. Ekins, Presentation entitled "Why we should move towards	11.04.88
non-isotopic immunoassay?" (Ekins)	
65. Lysov et al. <u>Doklady Biochemistry</u> , Vol. 303, 436-438 "A	00.12.88
new method for Determining the DNA Nucleotide Sequence by	
Hybridisation with Oligonucleotides"	
66. Witness statement of Prof E Southern describing a	00.07.87
presentation given by a collegue of Aishi Wada in Japan	
(Wada)	

The Affymetrix case on invalidity is set out in the Amended Particulars of Objections (Document No. 12) which was filed and in the public domain and in their Opening Submission (Document No. 1). Affymetrix's Opening Submission is now in the public domain (as it was filed with the EPO by one of the opponents to Affymetrix's patent EP 0 619 321) and provides a detailed outline of the evidence Affymetrix was relying on to attack the validity of OGT's patent.

Affymetrix served three expert reports (with supplemental reports in reply) that all contained evidence relating to the validity of OGT's patent 0 373 203. Affymetrix also served two witness statements, but these do not contain any evidence dealing with the validity of OGT's patents. The expert reports relied on were as follows:

**Dr J Wetmur** (disclosure prohibited): This evidence provides an overview of the field of microarrays and then discusses the prior art cited against OGT's patent by Affymetrix. The allegations of anticipation and obviousness covered in the report are summarised in paragraphs 184 to 242 of the Affymetrix Opening Submission. Affymetrix also served a report by Dr Wetmur in the US litigation as set out below

**Dr A Cass** (disclosure prohibited): The report provides an opinion on the lack of enablement of OGT's patent and discusses the history of OGT's efforts to put the invention into effect (paragraphs 169-175 of the Opening Submission). It also discusses the experiment carried out by OGT as part of the proceedings (paragraphs 175 to 183 of the Opening Submission). The report also contains opinions on anticipation and obviousness as summarised in paragraphs 184 to 242 of the Affymetrix Opening Submission.

**Dr R Gamble** (disclosure prohibited): Gives evidence for Affymetrix as an expert familiar with pen plotters, ink-jet printers and laser typesetting on whether a person skilled in the art could have made large dense arrays using ink-jet technology from the teaching in the OGT patent. A summary of this evidence is set out in paragraphs 151 to 163 of the Affymetrix Opening Submission. This evidence covers the same ground as the declaration of Professor C Quate filed with the EPO by Affymetrix in January 1999 in opposition to OGT's patent. Professor Quate's Declaration is already of record and was cited by the Applicant in a previously filed IDS.

In addition a large amount of material has been filed with the Opposition Division of the EPO during the opposition to OGT's 0 373 203 patent. All of the relevant documents have all been filed with the USPTO. Included in those documents is the declaration of Professor C Quate which was filed with the EPO by Affymetrix in January 1999 in opposition to OGT's patent. Reference is made to this declaration in this note in relation to expert evidence on the use of on penplotters, ink jet printers and laser type setting.

There are also the following documents which were filed by OGT in the EPO opposition to Affymetrix's patent and could be relevant to arguments on questions of density in relation to Affymetrix's patent and whether there is an interference in fact.

DOCUMENTS FILED BY OGT IN OPPOSITION TO	
PATENT EPO 619 321	
Document No. and Document Description	
67. OGT Notice of Opposition	07.10.99
68. Statutory Declaration of E M Southern	07.10.99

#### Documents from the OGT v Affymetrix US Infringement Action

The following documents have been identified as potentially relevant to issues of validity:

Document No. and Document Description	Date
69. Defendant's Motion for Leave to File a Second Amended	07.04.00
Answer	
70. Expert Report of Dale Davis	16.08.00
71. Expert Report of Grant Morgan	17.08.00
Expert Report of Osman Basaran	18.08.00
72. Expert Report of Dr Elias James Corey	18.08.00
73. Expert Report of Dr James Wetmur	18.08.00
OGT Motion for Summary Judgment of Validity Under 35 U.S.C.	23.08.00

102 and 103	<del>,</del>
OGT Motion for Summary Judgment of Validity Under 35 U.S.C	07.09.00
112. 1 <sup>st</sup> Paragraph	
74. Affymetrix Memorandum of Points and Authorities in Support	07.09.00
of Affymetrix's Opposition to OGT's Motion for Summary	
Judgment of Validity	
75. Declaration of James G Wetmur in Support of Affymetrix's	07.09.00
Opposition to OGT's Motion for Summary Judgment of Validity	
76. Expert Rebuttal Report of Dr James Wetmur	08.09.00
77. Expert Report of Prof Martin Adelman	08.09.00
Expert Report Regarding Non-Enablement and Unenforceability of	21.09.00
Dr Elias James Corey	21.05.00
OGT Reply in Support of Its Motion for Summary Judgment of	28.09.00
Validity Under 35 U.S.C 112, 1 <sup>st</sup> Paragraph	20.07.00
78. Declaration of Dr Elias James Corey in Support of Affymetrix	21.09.00
Opposition to OGT's Motion for Summary Judgment of Validity	21.07.00
79. Pretrial Order Exhibits 1-5, 12-13	05.10.00
Expert Report of Dr Kevin Struhl	09.10.00
Expert Report of Dr Revin Strain	02.10.00
80. Transcript of Markman Hearing	30.10.00
ov. Hunseript of Markinan Hearing	30.10.00
References Cited by Affymetrix in US proceedings and not cited	
in UK proceedings or cited on PTO File For '637 or '270 Patents	
81. Wada Abstracts of presentations given at a conference entitled	
"International Workshop on Automatic and High Speed – DNA –	
Base Sequencing" in Japan on 7-9 July 1987. (Wada)	
82. Wallace et al Nucleic Acids Research 6(11) 3543-3557 (1979)	
83. Uwe Maskos thesis	
84. Bannwarth, W et al., <u>DNA</u> , Volume 5, No 5 (1986), "A System	
for the Simultaneous Chemical Synthesis of Different DNA	
Fragments on Solid Support".	
85. Lohrmann et al., "New Solid Supports for DNA Synthesis",	
Fourth Annual Congress for Recombinant DNA Research.	
86. U.S. Patent No. 5,348,855 (Dattagupta, et al.)	
"Assay for Nucleic Acid Sequences in an Unpurified Sample".	
87. Goldkorn et al., Nucleic Acid Research, 14(22), 1986, "A simple	
and efficient enzymatic method for covalent attachment of DNA to	
cellulose. Application for hybridization – restriction analysis and for	
in vitro synthesis of DNA probes".	
88. Duncan et al., Analytical Biochemistry, 169, 104-108 (1988)	
"Affinity Chromatography of a Sequence – Specific DNA Binding	
Protein Using Teflon-Linked Oligonucleotides".	
89. Voss et al., <u>Biochemical Society Transactions</u> , 165 <sup>th</sup> Meeting,	
London, 367,368 (1987), "A simple and efficient method for	
covalently attaching oligonucleotides to a cellulose support matrix".	
90. Nicholls et al, <u>Journal of Clinical Laboratory Analysis</u> , 3: 122-	
70. Inchons et al, <u>Journal of Chilical Labolatory Allarysis</u> , 3. 122-	

135, "Nucleic Acid Analysis by Sandwich Hybridization".	
91. Wallace et al., Nucleic Acids Research, 9(4), 879-894, (1981)	
"The use of synthetic oligonucleotides as hybridization probes. II.	
Hybridization of olignucleotides of mixed sequence to rabbit ß-	
globin DNA".	
92. File History for Serial No. 07/593,589.	
93. File History for Serial No. 07/772.625.	
94. Sproat et al., Nucleic Acids Research, 13(8), 2979-2987 (1985),	
"A new linkage for solid synthesis of oligodeoxyribonucleotides"	
95. Kremsky et al., Nucleic Acids Research, 15(7), 2891-2909	
(1987), "Immobilization of DNA via oligonucleotides containing an	1
aldehyde or caboxylic acid group at 5' terminus".	_
96. Wolf et al., Nucleic Acids Research, 15(7), 2911-2926 (1987),	
"Rapid hybridization of DNA attached to submicron latex particles".	
97. Atkinson et al., Nucleic Acids Research, 16(13) 6232 (1988), "A	
convenient procedure for the synthesis of oligodeoxyribonucleotide	
affinity columns for the isolation of mRNA".	
98. EPO 119 573 A1 (Johnson)	

The following experts prepared reports for Affymetrix:

Osman Basaran (filed under seal) Covers the use of ink jet printers or other print technology for the application of biological materials to a substrate. The evidence of Osman Basaran covers the same ground as the declaration of Professor C Quate filed with the EPO by Affymetrix in January 1999 in opposition to OGT's patent and the evidence given by Dr Gamble in the UK proceedings (A summary of which is set out in paragraphs 151 to 163 of the Opening Submission). Professor Quate's declaration gave evidence on penplotters, ink jet printers and laser type setting.

**Dale Davis** (Document No. 70 not filed under seal) This expert report relates to the question of whether OGT's '637 patent teaches one with knowledge and expertise in pen plotting to synthesize oligonucleotides.

Grant Morgan (Document No. 71 not filed under seal) This expert report relates to the question of whether OGT's '637 patent teaches one with knowledge and expertise in laser typesetting to use that technology to build precursor arrays.

Dr Elias Corey Prepared two reports. The earlier report (Document No. 72) was not filed under seal and focused on the Bannwarth (Document No. 84) and Geyson (Document No. 59) references and claims that they teach and enable every element of claim 1 of the '637 patent. The second report was filed under seal and presented Affymetrix's claims of non-enablement and of unenforceability. Affymetrix's allegations are generally set forth in its Motion for Leave to File a Second Amended Answer (Document No. 69) and the Pretrial Order (Document No. 79, Exhibits 1-5, 12-13 only). Dr. Corey criticized the experiments and conclusions reported in the '637 patent. He compared a statement in the thesis of Uwe Maskos (Document No. 83),

who was a graduate student in Prof. Southern's laboratory involved in many of the related experiments, to a statement in the '637 patent. In his thesis, Uwe Maskos stated: "After partial elution in 0.1 M NaCl no differential binding to the target was detectable, i.e. there was the same amount of binding to the shorter as to the longer oligo-t<sub>n</sub> under these conditions, as judged by autoradiography." (p. 58) In the '637 patent, it is reported: "... differential binding to the target is detectable, i.e., less binding to the shorter than the longer oligo-dT." (Col. 9:55-57) Affymetrix argued that Prof. Southern misstated the results of this experiment. Prof. Southern explained in his deposition testimony in the Affymetrix case and in the subsequent Mergen and Motorola cases that the two descriptions were of different autoradiographs of an experiment, which were prepared for different purposes. The report by Dr. Maskos related to an autoradiograph that demonstrated the ability to synthesize oligonucleotide probes at specific locations on a glass microscope slide by showing the absence of binding of a target nucleic acid anywhere but where the oligonucleotides were synthesized. For this purpose, it was helpful to overexpose the autoradiograph. The autoradiograph described in the '637 patent, on the other hand, was obtained to determine whether differential hybridisation could be detected. For this purpose, it would be important not to overexpose the autoradiograph. Dr. Corey also criticised examples 5 and 7 of the '637 patent and conclusions in the patent, claiming that the experimental results did not support the conclusions drawn. Prof. Southern believes these criticisms are all baseless. Notably, while defendants in subsequent litigations have been aware of all of the arguments made by and on behalf of Affymetrix, they have not raised these arguments, apparently confirming Prof. Southern's position that they are baseless.

Dr K Struhl (filed under seal) The report also provides an opinion supporting Affymetrix's claims of non-enablement and of unenforceability due to inequitable conduct. The report discusses the history of OGT's efforts to put the invention into effect by a consideration of Uwe Maskos' lab notebooks and thesis. Dr. Struhl criticised examples in the '637 patent and conclusions in the patent, claiming that the notebooks and thesis show that experimental results were misrepresented and did not support the conclusions drawn. The report also discusses the Wada reference (Document No. 81) and the claim that OGT withheld material prior art from the PTO including Wada and the Maskos thesis. Affymetrix's allegations as to inequitable conduct and the withholding of references from the PTO are generally set forth on page 6 in its Motion for Leave to File a Second Amended Answer and the Pretrial Order. The "Gitschier" reference that Affymetrix alleges should have been disclosed was never properly identified by Affymetrix or relied on by any of their experts in either the US or the UK litigation. The reference appears to be based on an answer given by Professor Southern in his deposition on 23 March 2000 when asked about a reference showing use of amethylammonium chloride for hydribization when he stated "I'm sure its referenced somewhere in my writings. Gitschier I think might be one of the names". In fact the reference appears to be a paper by Wood et al (Proc. Natl. Acad. Sci. (USA) vol. 82 pp 1585-1588 (1985)) and Jane Gitschier was one of the authors. The paper has been filed with the PTO in a previous IDS.

**Prof M Adelman** (Document No. 77 not filed under seal) A law professor who gave evidence on Affymetrix's argument that OGT had failed to disclose the Wada conference in sufficient detail to the Examiner for the Examiner to determine whether or not it would constitute prior art.

**Dr J Wetmur** (Document Nos. 75-76 not filed under seal) Evidence focuses on the Dattagupta prior art reference also cited in the UK proceedings and in the EPO. The report contains similar conclusions as in the report prepared by Dr Wetmur in the UK proceedings and summarised in paragraphs 189 to 199 of the Opening Submission.

The Affymetrix Memorandum of Points and Authorities in Support of Affymetrix's Opposition to OGT's Motion for Summary Judgment of Validity (Document No. 74) was also not filed under seal and this sets out in tables the case put forward on anticipation and obviousness. The remaining documents do not disclose anything additional that would be material to the question of validity. The majority of the expert reports can be filed with the USPTO and the ones that cannot do not add anything material.

#### **Documents from OGT v Mergen US Infringement Action**

The following documents have been identified as potentially relevant to issues of validity:

Document No. and Document Description	Date
99. Technology Tutorial Transcript	18.12.03
100. OGT's Slide Presentation for Technology Tutorial	18.12.03
101. Mergen's Slide Presentation for Technology Tutorial	18.12.03
102. Clontech's Slide Presentation for Technology Tutorial	18.12.03
103. Letter from Kirkland to Perkins Coie enclosing OGT Claim	30.04.04
Terms	
104. Mergen Claim Terms and Proposed Construction	30.04.04
Expert Report of Kent E Vrana	12.05.04
105. Expert Report of Paul Edward Purdue	12.05.04
Expert Report of Mark Schena	03.06.04
106. Rebuttal Expert Report of Paul Purdue	04.06.04
Rebuttal Expert Report of Kent E Vrana	04.06.04
107. Mergen's Third Set of Supplemental Responses to OGT's First	17.06.04
and Second Set of Interrogatories	
108. OGT's Claim Construction Brief	22.07.04
109. Mergen's Opening Claim Construction Brief	22.07.04
OGT's Motion and Memorandum in Support for Partial Summary	22.07.04
Judgment of Patent Validity and Enablement	

Mergen's Opening Brief in Support of Motion for Summary Judgment of Invalidity of the Asserted Claims of US Patent No	22.07.04
6,054,270	
Mergen's Opening Brief in Support of Motion for Summary	22.07.04
Judgment of Invalidity of Claim 1 of United States Patent No	
6,054,270 Pursuant to U.S.C. 112	
Mergen's Answering Brief to OGT's Claim Construction Brief	05.08.04
OGT's Opposition to Mergen's Motion for Summary Judgment of	05.08.04
Invalidity of the Asserted Claims of US Patent No. 6,054,270	
OGT's Brief in Support of Its Motion to Strike and Opposition to	05.08.04
Mergen's Motion for Summary Judgment of Invalidity of Claim 1 of	
United States Patent 6,054,270 Pursuant to 35 U.S.C. 112	
Declaration of David B Wallace	05.08.04
Declaration of Kent E Vrana	05.08.04
Mergen Limited's Opposition to OGT Limited's Motion for Partial	05.08.04
Summary Judgment of Patent Validity	
110. Mergen's Reply in Support of Its Motion for Summary	12.08.04
Judgment of Invalidity of Claim 1 of US patent No. 6,054,270	
Pursuant to 35 U.S.C 112	
111. Declaration of Norbert Stahl in Support of Mergen's Reply	12.08.04
Brief in Support of Its Motion for Summary Judgment of Invalidity	
of Claim 1 of United States Patent No. 6,054,270 Pursuant to 35	
U.S.C. 112	
OGT's Reply Brief in Support of Its Motion for Partial Summary	12.08.04
Judgment of Patent Validity	
Mergen's Reply in Support of Its Motion for Summary Judgment of	12.08.04
Invalidity of the Asserted Claims of US Patent No. 6,054,270	
112. OGT's Claim Construction Brief in Response to Mergen's	12.08.04
Claim Construction Briefing	
113. Order and Memorandum Opinion re Claim Terms	29.09.04
114. Order and Memorandum of opinion re Expert Reports	16.11.04
115. Order and Memorandum Opinion re Summary Judgment	19.11.04
116. Mergen Limited's Motion for Reconsideration of the Court's	03.12.04
Order Granting in Part OGT's Motion for Partial Summary	
Judgment of Infringement	
117. OGT's Opposition to Mergen Limited's Motion for	17.12.04
Reconsideration	
118. Mergen Reply in Support of Its Motion for Reconsideration	27.12.04
119. Letter from Richard K Hermann to Judge Jordan re claims	07.01.05
terms	
120. Order re Mergen's Motion for Reconsideration	07.01.05

Although a lot of the documents on the Court docket (Document No. 134) were filed under seal there are sufficient documents that were not filed under seal to be able to consider Mergen's arguments on validity of the '270 patent. Mergen's Third Set of

Supplemental Responses to OGT's First and Second Set of Interrogatories (Document No. 107) was not filed under seal and contains a full summary of Mergen's arguments on claim construction and invalidity.

The litigation involved the consideration by Judge Jordan of a number of motions for validity/invalidity of the '270 patent and the exclusion of expert evidence, as well as the briefs filed by each party on the question of claim construction. The Orders and Memorandums of Opinion on claim construction (Document No. 113), the exclusion of expert evidence (Document No. 114) and motions for summary judgment (Document No. 115) provide a thorough summary of the expert evidence and submissions made by each party on the question of validity and enablement.

The Mergen expert, Dr Purdue (Document Nos. 105-106 whose report was not filed under seal) sought to establish anticipation based on the Dattagupta application '726 (Document Nos. 86 and 93) and obviousness based on the Dattagupta application '726, the Stavrianopoulos US patent 4,994,373 patent (of record), the Gingeras PCT application WO 88/01302 (of record) and the Lysov article (Document No. 65) published in 1988, which were all references cited to the US Patent Examiner during the prosecution that resulted in the '270 patent. He also relied on a Khrapko article (Document No. 121) which was published in October 1989 in FEBS Vol 256 Nos 1-2 pages 118-122. See expert report and pages 9 to 16 of Judge Jordan's Memorandum of Opinion re Expert Reports.

Mergen also relied on the expert report of Mark Schena which was sealed under the Protective Order and cannot be disclosed. However, it is a short report that contains an opinion on whether Mergen's products infringed the claims of OGT's '270 patent and does not deal with issues of validity. The report is based on the argument that the '270 patent only covers in-situ synthesis of oligonucleotides and its contents are covered in Mergen's arguments described in other documents provided, including the Court's opinions, which are attached.

#### Documents from OGT v TeleChem US Infringement Action

The case settled before any Markman briefs were filed or expert reports exchanged. As a result only the following document has been identified as potentially relevant to issues of validity:

Document No. and Document Description	Date
122. Telechem's Responses to OGT's First Set of Interrogatories	01.10.04
(Nos. 1-16 [sic])	

Telechem's Responses to OGT's First Set of Interrogatories contain TeleChem's case on invalidity for lack of enablement, anticipation and obviousness including four references

(See Response 3 on pages 7 to 9). The only reference not cited to the US Patent Examiner on the '270 and '637 files is R Polsky-Cynkin et al "Use of DNA Immobilized on Plastic and Agarose Supports to detect DNA by Sandwich Hybridization" Clinical Chemistry, Vol 31, No 9, 1438-43 (1985) (Document No. 123).

#### Documents from OGT v BD Clontech US Infringement Action

The case settled before any Markman briefs were filed or expert reports exchanged. The following document has been identified as potentially relevant to issues of validity:

Document	Date
Clontech Responses to Plaintiff's First Set of Interrogatories	29.08.03

The Clontech Responses to Plaintiff's First Set of Interrogatories was filed under seal. It contains Clontech's case on invalidity of OGT's '270 patent. It only refers to references that were cited during the prosecution of the '270 and '637 patents. There are arguments based on the definition of 'oligonucleotide' and 'impermeable'.

### Documents from OGT v Motorola US Infringement Action

The case settled prior to the Markman hearing, but after Markman briefs had been filed. An expert report was filed by Motorola in support of its Markman Brief. The following documents have been identified as potentially relevant to issues of validity:

OGT v MOTOROLA INFRINGEMENT ACTION	
Document No. and Document Description	
Motorola's Supplemental Responses to Plaintiff's First Set of	O6.10.03
Interrogatories together with chart	
124. OGT's Markman Brief with Exhibits	03.12.03
125. Motorola's Response to Markman Brief	16.01.04
126. Motorola's Response to Markman Brief – Exhibits A-Z	
127. Motorola's Response to Markman Brief – Exhibits A(1)-	
G(1)	
128. Motorola's Response to Markman Brief – Exhibits 1-3	
129. OGT's Reply to Markman Brief	15.03.04
130. OGT's Reply to Markman Brief – Exhibit A Claim Chart	
131. OGT's Reply to Markman Brief – Exhibit 1-9	
132. OGT's Reply to Markman Brief – Exhibit H-R	

Motorola's Supplemental Responses to Plaintiff's First Set of Interrogatories were subject to the Protective Order as the document contains details of entities to whom Motorola had offered to sell the e-Sensor product claimed by OGT to infringe the '270 patent. The pleading also includes a lengthy list of references (over 80 references are included without any explanation as to why those patents or publications are relevant) included as "considered by Motorola as prior art or potential prior art with respect to the '270 patent". Most were taken from the file of the '270 patent, but the following were not:

US 4,225,575 (Piasio) US 4,596,697 (de Macorio) US 4,596,697 (de Macorio) US 4,682,891 (de Macorio) US 4,731.325 (Palva) US 4,792,520 (Stambrook) US 4,806,631 (Carrico) US 4,886,747 (Derynck) US 4,923,901 (Koester) US 5,008,080 (Brown) US 5,063,081 (Cozzette) US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown) US 4,965,190 (Woo)
US 4,596,697 (de Macorio) US 4,682,891 (de Macorio) US 4,731.325 (Palva) US 4,792,520 (Stambrook) US 4,806,631 (Carrico) US 4,886,747 (Derynck) US 4,923,901 (Koester) US 5,008,080 (Brown) US 5,063,081 (Cozzette) US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,789,628 (Nayak) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,596,697 (de Macorio) US 4,682,891 (de Macorio) US 4,731.325 (Palva) US 4,792,520 (Stambrook) US 4,806,631 (Carrico) US 4,886,747 (Derynck) US 4,923,901 (Koester) US 5,008,080 (Brown) US 5,063,081 (Cozzette) US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,789,628 (Nayak) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,731.325 (Palva) US 4,792,520 (Stambrook) US 4,806,631 (Carrico) US 4,886,747 (Derynck) US 4,923,901 (Koester) US 5,008,080 (Brown) US 5,063,081 (Cozzette) US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,333,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,792,520 (Stambrook) US 4,806,631 (Carrico) US 4,886,747 (Derynck) US 4,923,901 (Koester) US 5,008,080 (Brown) US 5,063,081 (Cozzette) US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,806,631 (Carrico) US 4,886,747 (Derynck) US 4,923,901 (Koester) US 5,008,080 (Brown) US 5,063,081 (Cozzette) US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,886,747 (Derynck) US 4,923,901 (Koester) US 5,008,080 (Brown) US 5,063,081 (Cozzette) US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,923,901 (Koester) US 5,008,080 (Brown) US 5,063,081 (Cozzette) US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 5,008,080 (Brown) US 5,063,081 (Cozzette) US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 5,063,081 (Cozzette) US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,789,628 (Nayak) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 5,126,276 (Fish) US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 5,149,622 (Brown) US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 5,200,051 (Cozzette) US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,133,639 (Harte) US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,378,344 (Zahradnik) US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,558,013 (Marinkovich) US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,613,566 (Potter) US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,689,405 (Frank) US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,789,628 (Nayak) US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,806,546 (Carrico) US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,775,631 (Saman) US 4,916,056 (Brown)
US 4,916,056 (Brown)
US 4,965,190 (Woo)
US 5,024,940 (Brenner)
US 5,075,077 (Durley)
US 5,132,097 (Van Deusen)
US 5,160,701 (Brown)
US 5,219,762 (Legendre)
US 5,242,797 (Hirschfield)
US 6,265,178 (Martin)
US 5,466,575 (Cozzette)
US 4,877,745 (Hayes)

# PCT Publication

W089/01157 (Ekins)
Other References
Kremsky et al., Nucleic Acids Research, 15, 7, 2891-2909 (1987)
Khrapko et al., FEBS Letters, 256, 1-2, 118-22 (Oct 1989)
Barone et al., Nucleic Acids Research, 12, 10, 4051-61 (1984)
Rosenthal et al., Tetrahedron Letters, 24, 16, 1691-94 (1983)
Agarwal et al., Angew. Chem. Internat. Edit., 11, 6,451-60 (1972)
Belagaje et al., Nucleic Acids Research, 8, 22, 5193-5205 (1980)
Djurhuus Matthes et al., Meth. Enzym, 154, 250-87 (1987)
Caruthers et al., Meth. Enzym. 154, 287-313 (1987)
Horvath et al., Meth. Enzym, 154, 314-326 (1987)

The pleading also includes a table setting out specific references from patents US 4,789,628 (Nayak), US 5,164,319 (Hafeman), US 4,994,373 (Stravianopoulos), US 4,558,013 (Marinkovich), US 4,133,639 (Harte), US 5,126,276 (Fish) and W089/01157 (Ekins) claiming that they anticipated claims 9 and 10 of the '270 patent and/or that claims 9 and 10 were obvious in view of those references.

The Applicant believes that the relevant references from this list are already cited in this application.

Respectfully submitted,

Edwin Southern

Warren M. Cheek, Jr.

Registration No. 33,367

Attorney for Applicant

WMC/dlk Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 December 20, 2005

Sheet 1 of 17			INFORMA'	TION DISCLOSURE STATEMENT	•		ØE.				
FORM PTO 1449 (m	nodified)			ATTY DOCKET NO. 99_1175	SERIAL 09/422		61. 4	8			
PAT	ENT AN	TMENT OF COMMERCE D TRADEMARK OFFICE NCES CITED BY APPLICAN	≣	APPLICANT Edwin Southern		,,000	BEC SO SOON				
(	(Use seve	eral sheets if necessary) to PTO: December 20, 2		FILING DATE October 22, 1999 GROUP 1631							
			U.	S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	62	4,689,405	8/1987	Frank et al.							
	86	5,348,855	9/1994	Dattagupta et al.	Dattagupta et al.						
FOREIGN PATENT DOCUMENTS											
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLA' YES	TION NO					
	61	1 526 708	9/1978	GB							
	98	0 119 573 A1	9/1994	EP	EP						
		OTHER	DOCUMENT(S) (I	Including Author, Title, Date, Pertine	ent Pages, Etc.)						
	1		ne Technology	ade, Affymetrix' Opening Su (OGT) v. Affymetrix, case r (ingdom.				s 1-81,			
· I	3			in the United Kingdom litiga 45, pages 1-5, January 28, 2				3T) v.			
	4		etween Oxford	Defendant's Response to the Identification of the Identification o							
:	5			ently Valid Claims, in the Uni ase no. HC 1999 04645, pa							
EXAMINER		·		DATE CONSIDER	PED						

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy this form with next communication to applicant.

Sheet 2 of 17			INFORMA	TION DISCLO	SURE STATEMENT		<del></del>			
FORM PTO 1449 (/	-	TMENT OF COMMERC		ATTY DOC 99_1175	KET NO.	SERIAL 09/422				
PAT	ENT AN	D TRADEMARK OFFICI	E	APPLICAN Edwin Sc						
	•	eral sheets if necessary) to PTO: December 20, 2	2005	FILING DATE GROUP October 22, 1999 1631						
			U.	S. PATENT DO	OCUMENTS		.*			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME CLASS SUBCLASS FILING D. APPROP						
	]		EOR	EICNI BATENT	DOCUMENTS					
	1	DOCUMENT	DATE		DOCUMENTS	CLASS	SUBCLASS	TRANSLA	TION	
		NUMBER	DATE	COUNTRY CLASS SUBCLASS TRANSLATIO YES N						
	<u> </u>	OTHER	DOCUMENT(S) (	Including Author	or, Title, Date, Pertinent	Pages Ftc )				
	6						otion hotuson			
			Richard Meade, Bristows, Statement of Reasons, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case no. HC 1999 04645, pages 1-4, June 30, 2000, London, United Kingdom.							
	7	Bird & Bird, Statement of Opposition, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case no. HC 1999 04645, pages 1-5, June 30, 2000, London, United Kingdom.								
	8	Bird & Bird, Re-Re-l Oxford Gene Techn United Kingdom.	Re-Amended F ology (OGT) v	Particulars of Affymetrix	of Objections, in the case no. HC 1999	e United King 0 04645, pag	gdom litigation bes 1-5, March 1	petween 13, 2001, Lon	ndon,	
	9	Alastair Wilson QC, Technology (OGT) v Kingdom.								
	10	Bird & Bird, Amende Technology (OGT) v Kingdom.								
	11	Richard Meade, Defence and Counterclaim of the First and Second Defendants, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case no. HC 1999 02517, pages 1-6, August 6, 1999, London, United Kingdom.								
	12	Richard Meade, Am litigation between O 15, 2001, London, U	xford Gene Te	chnology (0						
EXAMINER	1	<u> </u>	<del></del>		DATE CONSIDERED		<u> </u>		· · · · · · · · · · · · · · · · · · ·	

Sheet 3 of 17,			INFORMA	TION DISCLO	SURE STATEMENT					
FORM PTO 1449 (n	•	TMENT OF COMMERC	E	ATTY DOCI 99_1175	KET NO.		SERIAL I 09/422			
PAT	ENT AN	D TRADEMARK OFFIC	E	APPLICAN Edwin So						
		eral sheets if necessary) to PTO: December 20, 2	2005	1	FILING DATE GROUP October 22, 1999 1631					
			U.	S. PATENT DO	CUMENTS			•	_	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE						FILING DATE IF APPROPRIATE	
	<u> </u>									
i#	1	1			DOCUMENTS			I .		
		DOCUMENT NUMBER	DATE	DATE COUNTRY CLASS				SUBCLASS	TRANSLA YES	NO NO
	<u> </u>	OTHER	DOCUMENT(S) (	Including Author	or, Title, Date, Pertiner	nt Page	s Etc.)			1
	13	Manches, Re-Re-R Oxford Gene Techr Kingdom.	e-Amended Re	eply and De	fence of Counter	claim,	in the U			
	14	Dr. David R. Bentle Technology (OGT) London, United Kin	v. Affymetrix, c	Expert Repart Reparts	oort, in the United C 1999 04645 and	l Kingo d HC	lom litiga 1999 025	ation between 517, pages 1-3	Oxford Gene 88, January 3	0, 2001,
	15	Dr. David R. Bentle Oxford Gene Techr pages 1-124, Janua	nology (OGT) v	. Affymetrix	, case nos. HC 19					∖-1F,
	16	Oxford Gene Techr	Dr. David R. Bentley, Annex 1 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-17, January 30, 2001, London, United Kingdom.							
	17	Dr. David R. Bentle Oxford Gene Techr January 30, 2001, I	ology (OGT) v	. Affymetrix						
EXAMINER	I	<u>I</u>			DATE CONSIDERE					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy this form with next communication to applicant.

Sheet 4 of 17			INFORMA	TION DISCLO	SURE STATEMENT	·				
FORM PTO 1449 (n	•	TMENT OF COMMERCI		ATTY DOC 99_1175			SERIAL I 09/422			
PAT	ENT AN	ID TRADEMARK OFFICE  NCES CITED BY APPLICAN	E	APPLICAN Edwin So						,
	(Use seve	eral sheets if necessary) to PTO: December 20, 2			FILING DATE GROUP October 22, 1999 1631					
			U.		PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CL	ASS	SUBCLASS	FILING DA	
	1	1	FORE	EIGN PATENT	DOCUMENTS	ı		<del> </del>		_
	DOCUMENT DATE NUMBER			С	OUNTRY	CL	ASS	SUBCLASS	TRANSLA YES	ATION NO
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)										
	18	Oxford Gene Techn	Dr. David R. Bentley, Annex 3 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-2, January 30, 2001, London, United Kingdom.							
	19	Oxford Gene Techn	Dr. David R. Bentley, Annex 4 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-4, January 30, 2001, London, United Kingdom.							
	20	Dr. David R. Bentley Oxford Gene Techn January 30, 2001, L	ology (OGT) v.	Affymetrix	ort of Dr. David B , case nos. HC 1	entley, 999 04	in the Ui 645 and	nited Kingdom HC 1999 025	litigation bet	ween 12,
	21	Dr. David R. Bentley Oxford Gene Techn January 30, 2001, L	ology (OGT) v.	Affymetrix	ort of Dr. David B , case nos. HC 1	entley, 999 040	in the Ui 645 and	nited Kingdom HC 1999 0251	litigation bet 17, pages 1-8	ween 3,
	22	Oxford Gene Techno	Dr. David R. Bentley, Annex 7 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-2, January 30, 2001, London, United Kingdom.							
	23	Oxford Gene Techno	Dr. David R. Bentley, Annex 8 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-6, January 30, 2001, London, United Kingdom.							
EXAMINER	1		<del></del>		DATE CONSIDER	ED		-		

Sheet 5 of 17			INFORMA	TION DISCLO	SURE STATEMENT			<u></u>		
FORM PTO 1449 (n	•	TMENT OF COMMERCI	=	ATTY DOCI 99_1175	KET NO.	SERIAL 09/422		- , -		
PAT	ENT AN	D TRADEMARK OFFICE	E	APPLICAN' Edwin So		·· • • • · · · · · · · · · · · · · · ·				
		eral sheets if necessary) to PTO: December 20, 2	2005	FILING DATE GROUP October 22, 1999 1631						
			U.	S. PATENT DO	DCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DA		
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER	DATE	COUNTRY CLASS SUBCLASS TRANSLATION YES N						
	,	OTHER	DOCUMENT(S)	Including Autho	or, Title, Date, Pertinent	t Pages, Etc.)				
	24	Oxford Gene Techn	Dr. David R. Bentley, Annex 9 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-12, January 30, 2001, London, United Kingdom.							
	25	Dr. David R. Bentley, Annex 10 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-14, January 30, 2001, London, United Kingdom.								
	26	Dr. David R. Bentley Oxford Gene Techn January 30, 2001, L	ology (OGT) v.	. Affymetrix,	ort of Dr. David Be , case nos. HC 199	entley, in the 99 04645 and	United Kingdor I HC 1999 025	n litigation be 17, pages 1-5	tween 5,	
	27	Dr. David R. Bentle Oxford Gene Techn January 30, 2001, L	ology (OGT) v.	. Affymetrix,						
	28	Dr. David R. Bentley Oxford Gene Techn January 30, 2001, L	ology (OGT) v.	. Affymetrix,						
	Dr. David R. Bentley, Annex 14 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-8, January 30, 2001, London, United Kingdom.									
	30	Dr. David R. Bentley Oxford Gene Techn January 30, 2001, L	ology (OGT) v.	. Affymetrix,						
EXAMINER					DATE CONSIDERED	)	<del></del>			

Sheet 6 of 17	Sheet 6 of 17 INFORMATION DISCLOSURE STATEMENT									
FORM PTO 1449 (n	•			ATTY DOC 99_1175			SERIAL 1 09/422,			
PAT	ENT AN	TMENT OF COMMERCE ID TRADEMARK OFFICE NCES CITED BY APPLICAN	E	APPLICAN Edwin So			···-			
	(Use seve	eral sheets if necessary) to PTO: December 20, 2		FILING DA	TE			GROUP 1631		
	10iiiiiii	10710. 500011.50. 20, 2						1031		
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	.S. PATENT DO	NAME	CL	LASS	SUBCLASS	FILING DATE APPROPRIA	
	<del>                                     </del>		<u> </u>	<del>                                     </del>		<del>                                     </del>				
	<u></u>		FOR!	FIGN PATENT	r documents	1		<u></u>		
		DOCUMENT NUMBER	DATE		OUNTRY	CI	LASS	SUBCLASS	TRANSLATIO YES	ON NO
		OTHER	DOCUMENT(S)	Including Auth	or, Title, Date, Pertin	nent Page	s, Etc.)			
Dr. David R. Bentley, Annex 16 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-38, January 30, 2001, London, United Kingdom.										
	32	Dr. David R. Bentley, Annex 17 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-4, January 30, 2001, London, United Kingdom.								
	33	Oxford Gene Techni	Dr. David R. Bentley, Annex 18 to Expert Report of Dr. David Bentley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517, pages 1-2, January 30, 2001, London, United Kingdom.							
	34	Dr. David R. Bentley Oxford Gene Technol January 30, 2001, L	ology (OGT) v.	. Affymetrix						een
	35	Prof. Wolfgang Pflei Technology (OGT) v 19, 2001, Konstanz,	v. Affymetrix, c							
	36	Dr. David B. Wallace between Oxford Ger 1-55, January 18, 20	ne Technology	/ (OGT) v. A	Affymetrix, case r					
	37	Dr. David B. Wallace litigation between O pages 1-25, January	xford Gene Te	echnology (C	OGT) v. Affymetr					
	38	Dr. David B. Wallace litigation between O pages 1-24, January	xford Gene Te	echnology (C	OGT) v. Affymetr	ren Wal	lace, P.E e nos. H(	E., PH.D., in the C 1999 04645	e United Kingdo and HC 1999 07	im 2517,
EXAMINER	<u></u>		<u> </u>		DATE CONSIDER				<u></u>	

Sheet 7 of 17			INFORMA	TION DISCLO	SURE STATEMENT	r	-				
FORM PTO 1449 (n	•	THENT OF COMMEDO	_	ATTY DOC! 99_1175			SERIAL 1 09/422,				
PAT	ENT AN	TMENT OF COMMERCE  TRADEMARK OFFICE  TO TRADE BY ARREST CAN	E	APPLICAN Edwin So							
,	(Use seve	NCES CITED BY APPLICAN eral sheets if necessary) to PTO: December 20, 2		FILING DAT	FILING DATE GROUP						
Date 3t	Dimiteu	to PTO: December 20, 2		October 2				1631			
	T			.S. PATENT DO		Т		<u> </u>			
*EXAMINER INITIAL	ļ	DOCUMENT NUMBER	DATE		NAME	Cr	LASS	SUBCLASS	FILING DA APPROPI		
	FOREIGN PATENT DOCUMENTS										
	<u> </u>	DOCUMENT NUMBER	DATE						TRANSLA YES	ATION NO	
		OTHER	DOCUMENT(S) (	Including Auth	or, Title, Date, Pertin	nent Page	s, Etc.)			-	
	Dr. Paul H. Silverman, Statement of Dr. Paul Hyman Silverman and Exhibit PS-1, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645 and HC 1999 02517 pages 1-2 and 1-8, November 22, 2000, Irvine, California.										
	40	Prof. Edwin M. Southern, First Witness Statement of Edwin Mellor Southern, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 04645, pages 1-10, May 1, 2000, Oxford, United Kingdom.									
	41	Prof. Edwin M. Sout Kingdom litigation b pages 1-14, May 1,	etween Oxford	d Gene Tech	hnology (OGT) v					ted	
	43	Prof. Edwin M. Sout Kingdom litigation b pages 1-41, May 1,	etween Oxford	d Gene Tech	hnology (OGT) v					ted	
	44	Prof. Edwin M. Sout Kingdom litigation b pages 1-58, May 1,	etween Oxford	d Gene Tech	hnology (OGT) v					ted	
	45	Prof. Edwin M. Sout between Oxford Ger 2001, Oxford, United	ne Technology								
	46	Prof. Edwin M. Sout litigation between O 22, 2001, Oxford, U	xford Gene Te	chnology (C							
EXAMINER				<del></del>	DATE CONSIDER	 RED	<u>.                                    </u>				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 8 of 17			INFORMA	TION DISCLO	SURE STATEMENT						
FORM PTO 1449 (A		TMENT OF COMMERC	F	ATTY DOC 99_1175			RIAL NO. 0/422,803				
PAT	ENT AN	D TRADEMARK OFFICE	E	APPLICAN Edwin Sc	•						
	(Use sevi	eral sheets if necessary) to PTO: December 20, 2			FILING DATE GROUP October 22, 1999 1631						
			U.	S. PATENT D	S. PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	1	T	FORE	EIGN PATENT	DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY CLASS SUBCLASS				TRANSLATION YES NO			
	<u> </u>	OTHER	DOCUMENT(S) (	Including Auth	or, Title, Date, Pertiner	nt Pages, Etc	c.)	.,.			
	47	Peter Jay Coassin, Witness Statement of Peter Jay Coassin, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 02517, pages 1-4, January 22, 2001, Fullerton, California.									
	48	Dr. Timothy S. Fell, Witness Statement of Timothy Stephen Fell, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 02517, pages 1-11, January 18, 2001, Oxford, United Kingdom.									
	49	Dr. Timothy S. Fell, between Oxford Ge Oxford, United King	ne Technology	tness State	ment of Timothy of Stymetrix, case no	Stephen F os. HC 19	Fell, in the United K 99 02517, pages 1	Cingdom litigation -5, January 18, 2001,			
	50	Dr. Timothy S. Fell, between Oxford Ger Oxford, United King	ne Technology					(ingdom litigation -6, January 18, 2001,			
	51	Dr. Timothy S. Fell, between Oxford Gel Oxford, United King	ne Technology					ingdom litigation -8, January 18, 2001,			
	52	Dr. Timothy S. Fell, between Oxford Ger 2001, Oxford, United	ne Technology	tness State (OGT) v. A	ment of Timothy S	Stephen Fos. HC 19	Fell, in the United K 99 02517, pages 1	ingdom litigation -11, January 18,			
	53	between Oxford Ger	Dr. Timothy S. Fell, Annex 5 to Witness Statement of Timothy Stephen Fell, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 02517, pages 1-2, January 18, 2001, Oxford, United Kingdom.								
	54	Dr. Timothy S. Fell, between Oxford Ger 2001, Oxford, United	ne Technology	tness State (OGT) v. A	ment of Timothy S	Stephen F os. HC 19	Fell, in the United K 99 02517, pages 1	ingdom litigation -11, January 18,			
EXAMINER			<del></del>		DATE CONSIDERE	D	·				

Sheet 9 of 17,			INFORMA	TION DISCLO	SURE STATEMENT							
FORM PTO 1449 (n	nodified)		III OIIIIA	ATTY DOCK			SERIAL N	10.				
U.S.	DEPAR	TMENT OF COMMERC	E	99_1175			09/422,	803				
LIST OF	REFEREI	D TRADEMARK OFFICI NCES CITED BY APPLICAN		APPLICANT Edwin Southern								
	•	eral sheets if necessary) to PTO: December 20, 2	2005	FILING DAT				GROUP 1631				
			U.:	S. PATENT DO	PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CIV	ASS	SUBCLASS	FILING DA APPROPI			
			FORE	EIGN PATENT	DOCUMENTS	•						
		DOCUMENT NUMBER	DATE	co	DUNTRY	CD	ASS	SUBCLASS	TRANSLA YES	ATION NO		
								T				
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)												
	55		Stewart L. Huxley, Witness Statement of Stewart Leonard Huxley, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 02517, pages 1-2, January 8, 2001, Oxford, United Kingdom.									
	56		artin G. Johnson, Witness Statement of Martin George Johnson, in the United Kingdom litigation between xford Gene Technology (OGT) v. Affymetrix, case nos. HC 1999 02517, pages 1-7, January 19, 2001, Oxford, nited Kingdom.									
	57	Ekins R., "Multi-ana 155-168, 1989.	lyte immunoas	say", Journ	al of Pharmace	utical &	Biomedi	cal Analysis, \	Vo. 7, No. 2, р	op.		
	58	Kimura et al., "An In 4, pp. 41-52, 1988.	nmobilized Enz	zyme Memb	orane Fabrication	n Metho	d using a	an Ink Jet No	zzle", Biosens	sors, Vol.		
	59	Geysen et al., "Stra 102, pp. 259-274, 1		pe analysis	using peptide s	synthesis	s", Journ	al of Immuno	logical Metho	ds, Vol.		
	60	Monaco et al., "Hun p. 90, 1989.	nan Genome Li	inking With	Cosmids and Y	east Art	ificial Ch	romosomes",	abstract from	ı CSHS,		
	63	Dr. Edwin Southern 0 619 321, pp. 1-17				ern, in t	he Oppo	sition Procee	dings against	EP No.		
	64	Ekins R., "Why we son Molecular Probe								nposium		
	65	Lysov et al., "A New Oligonucleotides", [							n with			
EYAMINED	·	l			DATE CONSIDER	ED						

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy this form with next communication to applicant.

****							<del></del>			
Sheet 10 of 17			INFORMA	TION DISCLO	SURE STATEMENT					
FORM PTO 1449 (/	•	TMENT OF COMMERC	F	ATTY DOC 99_1175			RIAL NO. 0/422,803			
PAT	TENT AN	D TRADEMARK OFFICI	E	APPLICAN Edwin So	•			-		
	(Use seve	eral sheets if necessary) to PTO: December 20, 2			FILING DATE GROUP October 22, 1999 1631					
				S. PATENT D						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING D		
								7111101		
	ļ					·				
		<u> </u>	FORI	EIGN PATENT	DOCUMENTS				<del></del>	
		DOCUMENT NUMBER	DATE	1	OUNTRY	CLASS	SUBCLASS	TRANSL YES	ATION NO	
		Nomber	<u> </u>					120		
	<del>-</del>	OTHER	DOCUMENT(S) (	Including Auth	or, Title, Date, Pertine	ent Pages Etc	c)	<u> </u>	1	
Professor Edwin Southern, Witness Statement of Professor Edwin Mellor Southern, in the United Kingdom litigation between Oxford Gene Technology (OGT) v. Affymetrix, case no. HC 1999 02517, pp. 1-40, January 2000, Kidlington, United Kingdom.										
	67		Bird and Bird, Notice of Opposition, in the Opposition Proceedings against EP No. 0 619 321 filed by Oxford Gene Technology, pp. 1-15, Oct. 1999, London, United Kingdom.							
	68	Dr. Edwin Southern 0 619 321, pp. 1-17				ern, in the	Opposition Procee	dings agains	EP No.	
	69	Morris, Nichols, Ars States litigation beto Delaware, CA No. 9	ween Oxford G	ene Techn	ology (OGT) v. At	ffymetrix, l				
	70	Dale Davis, Expert I v. Affymetrix, U.S. D Delaware.								
	71	Grant Morgan, Expe (OGT) v. Affymetrix, Atascadero, Califori	, U.S. District C							
	72	Dr. Elias Corey, Exp Technology (OGT) v 2000, Wilmington, D	v. Affymetrix, U							
	73	Dr. James Wetmur, Technology (OGT) v 2000, Wilmington, D	v. Affymetrix, U							
	74	Morris, Nichols, Ars OGT's Motion for St Technology (OGT) v September 2000, W	ummary Judgm v. Affymetrix, U	nent of Vali J.S. District	dity, in the United	l States liti	gation between Ox	ford Gene		
EXAMINER	•				DATE CONSIDERE	D		<del></del>		

Sheet 11 of 17			INFORMA	TION DISCLO	OSURE STATEMENT	·					
FORM PTO 1449 (n	•	RTMENT OF COMMERC	: <b>F</b>	ATTY DOC 99_1175			SERIAL I 09/422,				
PAT	TENT AN	ID TRADEMARK OFFICE	E	APPLICAN Edwin So							
	(Use seve	eral sheets if necessary)		FILING DA	FILING DATE GROUP						
Date of	10mmee	10 PTO. December 20, 2	2005	October 22, 1999 1631							
	т	Τ	<u>u,</u>	S. PATENT D	S. PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CL	LASS	SUBCLASS	FILING DA APPROPI		
			<u></u>								
		т	FORI	EIGN PATENT	T DOCUMENTS			<del> </del>	т		
	ļ	DOCUMENT NUMBER	DATE	C	COUNTRY	CL	LASS	SUBCLASS	TRANSLA YES	ATION NO	
	<del></del>	OTHER	DOCUMENT(S) (	Including Auth	nor, Title, Date, Pertine	ent Page	s, Etc.)				
	75	Summary Judgment	. James Wetmur, Declaration of James G. Wetmur in Support of Affymetrix's Opposition to OGT's Motion for immary Judgment of Validity, in the United States litigation between Oxford Gene Technology (OGT) v. fymetrix, U.S. District Court for the District of Delaware, CA No. 99-348, p. 1, September 2000, Palo Alto, elifornia.								
	76	Oxford Gene Techn	r. James Wetmur, Expert Rebuttal Report of Dr. James G. Wetmur, in the United States litigation between xford Gene Technology (OGT) v. Affymetrix, U.S. District Court for the District of Delaware, CA No. 99-348, pp. 45, September 2000, Palo Alto, California.								
	77	Dr. Martin Adelman, Technology (OGT) v 2000, Washington,	v. Affymetrix, U								
	78	Dr. Elias Corey, Dec Summary Judgment Affymetrix, U.S. Dist Massachusetts.	it of Validity, in	the United	States litigation I	betwee	n Oxford	Gene Techno	ology (OGT) v	<i>1</i> .	
	79	Pretrial Order Exhib Affymetrix, U.S. Dist Delaware.									
	80	Transcript of Markm Affymetrix, U.S. Dist Delaware.									
	81	Wada A., Abstracts Sequencing, pp. 2-1				p on A	utomatic	and High Spe	ed DNA Base	<b>)</b>	
	82	Wallace et al., "Hybi base pair mismatch'							e effect of sin	ıgle	
	83	Uwe Maskos, "A nov Oxford, pp. 2-161, N				/sis", M	askos Ti	nesis submitte	d to Universit	y of	
EXAMINER			,		DATE CONSIDER	.ED					

Sheet 12 of 17			INFORMA	TION DISCLO	SURE STATEMENT						
FORM PTO 1449 (r.	•	THENT OF COMMERC	=	ATTY DOC 99_1175			SERIAL N 09/422,				
PAT	ENT AN	TMENT OF COMMERCI D TRADEMARK OFFICI NCES CITED BY APPLICAN	E	APPLICAN Edwin Sc		<u> </u>			_		
	(Use seve	eral sheets if necessary) to PTO: December 20, 2	. ,	FILING DATE GROUP October 22, 1999 1631							
			U.S	S. PATENT D	PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME CLASS SUBCLASS FILING DA' APPROPR							
		-									
			FORE	IGN PATENT	DOCUMENTS						
		DOCUMENT NUMBER	DATE	С	OUNTRY	CL	ASS	SUBCLASS	TRANSLA YES	ATION NO	
OTHER DOCUMENT(S) (Incl					or, Title, Date, Pertin	ent Pages	, Etc.)				
Bannworth, W. et al., "A System for the Simultaneous Chemical Synthesis of Different DNA Fragments on Sol Support", DNA, Vol. 5, No. 5, pp. 413-419, 1986.								on Solid			
	85		ohrmann, R. et al., "New Solid Supports for DNA Synthesis", Fourth Annual Congress for Recombinant DNA esearch, p. 122, 1984.								
	87	Goldkorn, T. et al., " Application for hybri Research, Vo. 14, N	dization-restric	tion analys	sis and for in vitro					);	
	88	Duncan, C. et al., "A Oligonucleotides", A						ing Protein Us	sing Teflon-lin	iked	
	89	Voss et al., "A simple matrix", Biochemica	le and efficient I Society Trans	method for sactions, 16	r covalently attac 65th meeting, Lo	ching oli ndon, p	gonucleo p. 367-3	otides to a cel 68, 1987.	lulose suppoi	rt	
	90	Nicholls, P. et al., "N Vol. 3, pp. 122-135,		alysis by S	Sandwich Hybridi	zation",	Journal	of Clinical Lal	poratory Anal	ysis,	
	91	Wallace, R. et al., "7 oligonucleotides of r 879-894, 1981.								p.	
	92	File wrapper of S.N.	07/593,589 no	ow abandoi	ned.						
	93	File wrapper of S.N.	07/772,625 m	aturing into	US 5,348,855 c	on Septe	ember 19	994 to Dattagu	ıpta et al.		
EXAMINER	1.			<u></u>	DATE CONSIDER	ED					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy this form with next communication to applicant.

Sheet 13 of 17			INFORMA	TION DISCLO	SURE STATEMENT					
FORM PTO 1449 (n	nodified)			ATTY DOC			SERIAL N	10.		
	·	TMENT OF COMMERC	E	99_1175			09/422,			
		D TRADEMARK OFFICI NCES CITED BY APPLICAN		APPLICAN Edwin So						
	•	eral sheets if necessary) to PTO: December 20, 2	2005		FILING DATE GROUP October 22, 1999 1631					
			U.S	L	PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	ASS	SUBCLASS	FILING DA	
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER	DATE	С	OUNTRY	CLA	ASS	SUBCLASS	TRANSLA YES	ATION NO
		OTHER	Including Auth	or, Title, Date, Pertin	ent Pages,	, Etc.)	•			
	94 Sproat, B. et al., "A new linkage for solid phase synthesis of oligonucleotides", Nucleic Acids Research, Vol. 13, No. 8, pp. 2979-2987, 1985.								Vol. 13,	
	95		emsky, J. et al., "Immobilization of DNA via oligonucleotides containing an aldehyde or carboxylic acid group the 5' terminus", Nucleic Acids Research, Vol. 15, No. 7, pp. 2891-2909, 1987.							
	96	Wolf, S. et al., "Rap Research, Vol. 15, I				to submi	cron late	ex particles", I	Nucleic Acids	
	97	Atkinson, T., "A con of mRNA", Nucleic A	venient proced Acids Research	lure for the h, Vol. 16,	synthesis of olig No. 13, p. 6232,	godeoxyr 1988.	ribonucle	eotide affinity	columns for is	solation
	99	Court Transcript of v. Mergen Ltd et al., Wilmington, Delawa	U.S. District C	torial, in the	e United States I e District of Dela	litigation ware, CA	betweer No. 02	n Oxford Gene -1695, pp. 1-7	e Technology 72, December	(OGT) r 2003,
	100	Blank Rome LLP, O (OGT) v. Mergen Ltd 2003, Wilmington, D	d et al., U.S. Di							
	101	Ashby & Geddes, D States litigation betw of Delaware, CA No	veen Oxford G	ene Techn	ology (OGT) v. N	/lergen L	td et al.,	U.S. District		
	102	Patton Boggs LLP, I the United States liti the District of Delaw	igation betwee	n Oxford G	ene Technology	(OGT) v	. Merge	n Ltd et al., U	.S. District Co	
	103	Kirkland & Ellis LLP between Oxford Ger No. 02-1695, pp. 1-6	ne Technology	(OGT) v. N	Nergen Ltd et al.	GT's Clair , U.S. Di	m Terms strict Co	in the United ourt for the Dis	d States litiga trict of Delaw	tion vare, CA
EXAMINER					DATE CONSIDER	RED				-

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy this form with next communication to applicant.

Sheet 14 of 17			INFORMA	TION DISCLO	SURE STATEMENT	-				
FORM PTO 1449 (	,	TMENT OF COMMERC	E	ATTY DOC 99_1175			SERIAL I 09/422			
PA <sup>-</sup>	TENT AN	ID TRADEMARK OFFIC	E	APPLICAN Edwin Sc	•	· •	<u> </u>			
	(Use seve	eral sheets if necessary) to PTO: December 20, 2		FILING DATE GROUP October 22, 1999 1631						
			U.	S. PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	ASS	SUBCLASS	FILING DA	
	· · · · · · · ·	T	FORE	EIGN PATENT	DOCUMENTS	ı — — —		I		
		DOCUMENT NUMBER	DATE	C	OUNTRY	CLA	ASS	SUBCLASS	TRANSLA YES	TION NO
	<b>.</b>	OTHER	DOCUMENT(S)	Including Auth	or, Title, Date, Pertin	ent Pages,	, Etc.)			
	Perkins Coie LLP, Mergen Ltd.'s Claim Terms and Proposed Construction, in the United States litigation between Oxford Gene Technology (OGT) v. Mergen Ltd et al., U.S. District Court for the District of Delaware, CA No. 02-1695, pp. 1-7, April 2004, Menlo Park, California.									
	105	Gene Technology (	Or. Paul Purdue, Expert Report of Paul Edward Purdue Ph.D., in the United States litigation between Oxford Gene Technology (OGT) v. Mergen Ltd et al., U.S. District Court for the District of Delaware, CA No. 02-1695, pp. 1-10, May 2004, New York, NY.							
	106	Dr. Paul Purdue, Ex Gene Technology ( pp. 1-13, June 2004	OGT) v. Merge	n Ltd et al.,	rd Purdue Ph.D. U.S. District Co	, in the l urt for th	Jnited S ne Distri	itates litigation ct of Delaware	between Oxf , CA No. 02-1	ord 695,
	107	Potter Anderson & ( Technology Ltd's Fi Technology (OGT) June 2004, Wilming	rst and Second v. Mergen Ltd e	d Set of Inte et al., U.S. I	errogatories, in th	ne Unite	d States	litigation betw	veen Oxford C	Sene
	108	Blank Rome LLP, C between Oxford Ge No. 02-1695, pp. 1-	ne Technology	(OGT) v. N	flergen Ltd et al.,	truction , U.S. Di	Brief, in	the United St ourt for the Dis	ates litigation trict of Delaw	are, CA
	109	Potter Anderson & 0 litigation between O Delaware, CA No. 0	xford Gene Te	chnology ((	DGT) v. Mergen	Ltd et al	l., U.Ş. [			
	110	Potter Anderson & 0 Invalidity of Claim 1 litigation between O Delaware, CA No. 0	of United State exford Gene Te	es Patent N chnology (0	IO. 6,054,270 Pt DGT) v. Mergen	ursuant t Ltd et al	to 35 U. I., U.S. [	S.C. 112, in th	e United Stat	es
	111	Potter Anderson & C Support of its Motio Pursuant to 35 U.S. et al., U.S. District C Delaware.	n for Summary C. 112, in the l	Judgment United State	of Invalidity of C es litigation betw	laim 1 o een Oxf	f United ford Ger	States Patent ne Technology	NO. 6,054,2 (OGT) v. Me	70 rgen Ltd
EXAMINER	•				DATE CONSIDER	ED		· · · · · · · · · · · · · · · · · · ·		

Shoot 45 to 6 47			INFORMA	TION DISCLO	CURE CTATEMENT					
Sheet 15°of 17			INFORMA		SURE STATEMENT					
FORM PTO 1449 (n		TMENT OF COMMERC	E	99_1175	KET NO.		SERIAL N 09/422,			
PAT	ENT AN	D TRADEMARK OFFICI	E	APPLICAN'						
	(Use seve	eral sheets if necessary)		FILING DAT	re	-		GROUP		
Date St	ubmitted	to PTO: December 20, 2	2005	October 2	22, 1999			1631		
	· · · · · ·		U.:	S. PATENT DO	CUMENTS	ľ				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	ss	SUBCLASS	FILING DA APPROPE	
<del></del>	<u>.                                    </u>	L	FORE	I EIGN PATENT	DOCUMENTS	<u></u>		<b></b>		
		DOCUMENT	DATE		DUNTRY	CLA	ss	SUBCLASS	TRANSLA	
		NUMBER							YES	NO
		OTUEN	DOCUMENTO:	la abodia a Aodh	Title Dete Destin	4 P	<b>540.</b> \			
	T		· • ·		or, Title, Date, Pertine					
	112	Construction Briefin	nk Rome LLP, Oxford Gene Technology's Claim Construction Brief In Response to Mergen's Claim Instruction Briefing, in the United States litigation between Oxford Gene Technology (OGT) v. Mergen Ltd et U.S. District Court for the District of Delaware, CA No. 02-1695, pp. 1-118, August 2004, Wilmington, aware.							
	113	between Oxford Ge	Order and Memorandum Opinion of the U.S. District Court on Claim Construction, in the United States litigation between Oxford Gene Technology (OGT) v. Mergen Ltd et al., U.S. District Court for the District of Delaware, CA							
	114	Order and Memorar between Oxford Ge No. 02-1695, pp. 1-	ne Technology	(OGT) v. N	lergen Ltd et al.,	, U.S. Dis				
	115	Order and Memorar between Oxford Ge No. 02-1695, pp. 1-	ne Technology	(OGT) v. N	lergen Ltd et al.,	, U.S. Dis				
	116	Potter Anderson & ( Part Oxford Gene T States litigation bett of Delaware, CA No	echnology Lim ween Oxford G	ited's Motio ene Techno	n for Partial Sun ology (OGT) v. M	nmary Ju Nergen L	udgmen td et al.	t of Infringeme , U.S. District (	ent, in the Uni	ited
	117	Blank Rome LLP, C Reconsideration, in U.S. District Court fo Delaware.	the United Sta	ites litigation	n between Oxfor	d Gene	Techno	logy (OGT) v.	Mergen Ltd e	et al.,
	118	Potter Anderson & ( Court's Order, in the District Court for the	United States	litigation b	etween Oxford C	Gene Tec	chnolog	y (OGT) v. Me	rgen Ltd et al	I., U.S.
	119	Blank Rome LLP, L Technology (OGT) v January 2005, Wilm	v. Mergen Ltd e	et al., U.S. [						
EXAMINER	•				DATE CONSIDER	ED				- · · · · · · · · · · · · · · · · · · ·

Sheet 16 of 17			INFORMA	TION DISCLOSURE STATEMEN	<u>T</u>					
FORM PTO 1449 (n	-	TMENT OF COMMERC	-	ATTY DOCKET NO. 99_1175	SERIAL 09/422					
PAT	ENT AN	TMENT OF COMMERCI D TRADEMARK OFFICI	Ē	APPLICANT Edwin Southern	<del></del>					
	(Use seve	NCES CITED BY APPLICAL eral sheets if necessary)	• •	FILING DATE						
Date Si	ubmitted	to PTO: December 20, 2	2005	October 22, 1999 1631						
	Т	T	U.	S. PATENT DOCUMENTS	T					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME CLASS SUBCLASS FILING DATE APPROPRIA						
			FORE	EIGN PATENT DOCUMENTS	<del></del>					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA YES	TION NO		
		OTHER	DOCUMENT(S)	Including Author, Title, Date, Pertir	nent Pages, Etc.)					
	120	Oxford Gene Techn	rder of the U.S. District Court on Mergen's Motion for Reconsideration, in the United States litigation betweer xford Gene Technology (OGT) v. Mergen Ltd et al., U.S. District Court for the District of Delaware, CA No. 2-1695, pp. 1-5, January 2005, Wilmington, Delaware.							
	121		hrapko, K. et al., "An oligonucleotide hybridization approach to DNA sequencing", FEBS, Vol. 256, Nos. 1-2, p. 118-122, October 1989.							
	122	First Set of Interroga	atories, in the l U.S. District Co	Felechem International, Inc. United States litigation betwo Dourt for the District of Delaw	ween Oxford Ge	ne Technology	(OGT) v. Tele	echem		
	123	Polsky-Cynkin, R. e Hybridization", Clini	t al., "Use of D cal Chemistry,	NA Immobilized on Plastic Vol. 31, No. 9, pp. 1438-14	and Agarose Si 443, 1985.	upports to Dete	ect DNA by Sa	ındwich		
	124	litigation between O	xford Gene Te	ord Gene Technology Limit echnology (OGT) v. Motorol , pp. 1-81, December 2003	a, Inc., U.S. Dis	trict Court for the	in the United S he Northeaste	States		
	125		OGT) v. Motoro	rola's Response Markman ola, Inc., U.S. District Court Chicago, Illinois.						
	126	between Oxford Gei	ne Technology	rola's Response Markman (OGT) v. Motorola, Inc., U 5, January 2004, Chicago, I	.S. District Cour	-Z, the United t for the Northe	States litigatio	on at of		
	127	between Oxford Ger	ne Technology	rola's Response Markman (OGT) v. Motorola, Inc., U. January 2004, Chicago, Illi	.S. District Cour					
	128	between Oxford Ger	ne Technology	rola's Response Markman (OGT) v. Motorola, Inc., U January 2004, Chicago, Illi	.S. District Cour	-3, the United S t for the Northe	States litigatio eastern Distric	n t of		
EXAMINER				DATE CONSIDER	RED		<del></del>			

Sheet 17 of 17			INFORMA	TION DISCLO	SURE STATEMENT						
FORM PTO 1449 (r		TMENT OF COMMERCI		ATTY DOC 99_1175			SERIAL N 09/422,				
PAT	ENT AN	D TRADEMARK OFFICE NCES CITED BY APPLICAN	E	APPLICANT Edwin Southern							
	(Use seve	eral sheets if necessary) to PTO: December 20, 2		FILING DATE GROUP October 22, 1999 1631							
		· · · · · · · · · · · · · · · · · · ·		<u> </u>	PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	O. TATENTO	NAME	CIA	ASS	SUBCLASS	FILING DA		
			FORE	EIGN PATENT	DOCUMENTS						
		DOCUMENT NUMBER	DATE	С	OUNTRY	CLA	ASS	SUBCLASS	TRANSLA YES	ATION NO	
		OTHER	DOCUMENT(S) (I	ncluding Auth	or, Title, Date, Pertin	ent Pages,	, Etc.)				
	Michael Best & Friedrich LLP, OGT's Reply to Markman Brief, in the United States litigation between Oxford Gene Technology (OGT) v. Motorola, Inc., U.S. District Court for the Northeastern District of Illinois, CA No. 02-9344, pp. 1-21, March 2004, Chicago, Illinois.										
	130	Technology (OGT) v	lichael Best & Friedrich LLP, OGT's Exhibit A Claim Chart, in the United States litigation between Oxford Gene echnology (OGT) v. Motorola, Inc., U.S. District Court for the Northeastern District of Illinois, CA No. 02-9344, p. 1-10, March 2004, Chicago, Illinois.								
	131	Michael Best & Fried Technology (OGT) v pp. 1-139, March 20	v. Motorola, Inc	., U.S. Dist	1-9, in the United trict Court for the	d States Northea	litigatior astern D	n between Oxi istrict of Illinoi	ford Gene is, CA No. 02	-9344,	
	132	Michael Best & Fried Technology (OGT) v pp. 1-222, March 20	v. Motorola, Inc	., U.S. Dist	H-R, in the Unite	d States Norther	litigatio astern D	n between Ox istrict of Illinoi	ford Gene is, CA No. 02	-9344,	
	133	Civil Docket for CA I Delaware, pp. 1-36,	No. 99-0348, C April 2005, Wi	Oxford Gend Ilmington, E	e Technology (O Delaware.	GT) v. A	Affymetri	x, Inc., U.S. D	istrict Court fo	or	
	134	Civil Docket for CA I Delaware, pp. 1-31,				GT) v. M	/lergen,	Ltd., U.S. Dist	rict Court for		
	135	Civil Docket for CA I Court for Delaware,					elechen	n International	l, Inc., U.S. D	istrict	
	136	Civil Docket for CA I Delaware, pp. 1-5, A				GT) v. N	lanogen	, Inc., U.S. Di	strict Court fo	r	
	137	Civil Docket for CA I Northeastern Distric					fotorola,	Inc., U.S. Dis	strict Court for	r the	
EXAMINER	<b>1</b>	-	<del></del>		DATE CONSIDER	ED		· · · ·			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy this form with next communication to applicant.